Tagged Articles

Eli Lilly & Co. 13 articles

Lilly pulls Axiron from Korean market

Eli Lilly & Co. has taken its topical testosterone replacement therapy Axiron off the market in Korea after gaining the blessing of the country’s Ministry of Food and Drug Safety. The company said that it made the decision to withdraw the treatment from the market in Korea due to several factors including “low male menopause awareness and the existence of substitutable medicines.” Axiron was developed by Australian pharmaceutical company Acrux and marketed by U.S.-based Lilly. It was approved by the U.S. Food and Drug Administration (FDA) in 2010 for the treatment of hypogonadism, a condition in which men do not ... Read More

Several testosterone side effects trials scheduled through 2019

Three trials involving testosterone side effects have taken place in 2017 and another 10 or 11 cases are scheduled to be tried through 2019, due to U.S. District Judge Matthew Kennelly’s interest in ensuring all plaintiffs and defendants have the benefit of timely bellwethers. The multidistrict litigation is consolidated in the U.S. District Court for the Northern District of Illinois and names a handful of testosterone manufacturers including AbbVie Inc., Eli Lilly & Co., and Auxilium Pharmaceuticals Inc. There are also state cases by Illinois residents against AbbVie. The Cook County judge is coordinating with Judge Kennelly on those cases. ... Read More

Eli Lilly announces settlement agreement of testosterone side effects cases

A month before facing its first bellwether trial in a multidistrict litigation involving testosterone side effects, Eli Lilly& Co., announced it had reached a global settlement in all cases filed against it. The drug company faced claims that the company failed to warn that its testosterone replacement therapy Axiron could cause potentially deadly heart attacks, strokes and blood clots. The pharmaceutical company told U.S. District Judge Matthew Kennelly that it had entered into a memorandum of understanding. As a result, Judge Kennelly canceled two upcoming trial dates – in January and March – involving Axiron. The trials involved the case ... Read More

Testosterone makers in tit-for-tat with insurance company

Medical Mutual of Ohio (MMO) filed a motion in Illinois federal court to compel drug companies AbbVie Inc. and Eli Lilly & Co., to produce documents in a putative class action over allegedly fraudulently marketing involving their testosterone replacement therapies. AbbVie and Lilly lashed back arguing that the insurance company had filed the motion prematurely without first trying to handle the dispute out of court. AbbVie said that had MMO done so, then it would have learned that AbbVie was planning to provide more information, which is more than MMO has done during the discovery process. The tit-for-tat stems from ... Read More

Lilly discontinues Axiron testosterone solutions

Eli Lilly & Co. is discontinuing two of its Axiron testosterone replacement therapy solutions and its authorized generic testosterone solution because there are multiple manufacturers that are currently selling the products, according to MPR. The discontinued products include Axiron 30mg /1.5mL with the NDC 0002-1975-90, Axiron 30mg/1.5mL with the NDC 0002-1975-61, and generic testosterone 30mg/1.5mL with the NDC 66993-963-89. Axiron solution is an androgen used to treat adult men with congenital or acquired primary hypogonadiasm or hypogonadotropic hypogonadism. It is supplied as a 90mL pump containing 60 metered pump or twist actuations with an applicator. Eli Lilly claims that the ... Read More

Physicians group calls for ban of drug ads aimed at consumers

The American Medical Association (AMA) is calling for an end to pharmaceutical companies’ direct-to-consumer advertising, saying the billions of dollars spent each year on the ads lead consumers to demand prescriptions that are often unnecessary and potentially dangerous. The AMA, which represents about a quarter of a million physicians nationwide, voted this week to take action against drug companies that heavily promote their treatments to consumers, arguing that such advertisement “inflates demand for new and more expensive drugs, even when these drugs may not be appropriate,” said AMA board chair-elect Patrice Harris in a statement. Case in point, manufacturers of ... Read More

Victims of testosterone side effects want their day in court

Robert Knapik felt tired and rundown, so much so he asked his doctor what could be causing the symptoms. His doctor diagnosed him with low testosterone, and suggested testosterone replacement therapy might help. It nearly killed him. After using the testosterone treatment Axiron, made by Eli Lilly & Co., for three months, Knapik began feeling pain in his arm and chest. He was later diagnosed with a heart attack. He learned that recent research had revealed that men who used testosterone replacement products were at an increased risk of blood clots, heart attacks, and strokes. Some users have even died. ... Read More

Judge refuses to dismiss Prozac birth defects lawsuit

A lawsuit filed by a woman who claims taking Eli Lilly & Co.’s antidepressant Prozac during pregnancy caused her child to be born with a heart defect will move forward after an Alabama federal court refused the drug company’s motion to dismiss the case. U.S. District Judge Keith Watkins found that the plaintiff, Dana Fields, had a genuine dispute against Eli Lilly, and that she could show factual causation that her doctor would not have prescribed the drug to her had he known the risks, even though the doctor is now deceased. Fields claims that in 1996 she took Prozac ... Read More

Fifth Circuit Court dismisses Actos bladder cancer appeal

The Fifth Circuit Court dismissed an appeal by Takeda Pharmaceuticals Co. and Eli Lilly & Co.’s involving a $36.8 million award to a plaintiff who claimed the companies’ type 2 diabetes drug Actos caused bladder cancer. The action comes just weeks after Takeda announced it would pay $2.4 billion to settle about 97 percent of Actos bladder cancer lawsuits. In 2011, Susan and Terrence Allen filed a lawsuit against the companies claiming that Terrence’s seven-year use of Actos to treat type 2 diabetes caused him to develop bladder cancer. They also claimed that the drug companies covered up cancer risks with ... Read More

Plaintiffs want information on cases of pancreatic cancer associated with type 2 diabetes drugs

A federal judge denied plaintiffs’ motion to gather drug companies’ analysis of pancreatic cancer cases among users of their type 2 diabetes drugs; however, his decision is still pending regarding plaintiffs’ request to gather adverse event reports involving those drugs submitted to the U.S. Food and Drug Administration (FDA). U.S. District Judge Anthony Battaglia is presiding over a multidistrict litigation (MDL) involving about 460 plaintiffs who allege they developed pancreatic cancer after taking one of four drugs in a class of type 2 diabetes drugs known as incretin mimetics. The lawsuits name Amylin Pharmaceuticals and Eli Lilly & Co., for the drug Byetta; Merck ... Read More